

## Printer Friendly

Printed from <http://www.researchandmarkets.com/reports/2114301>**Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019**

Description: Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019

## Summary

GlobalData, the industry analysis specialist, has released its new report, "Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Aplastic Anemia Therapeutics market. The report identifies the key trends shaping and driving the global Aplastic Anemia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Aplastic Anemia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

## Scope

The report provides information on the key drivers and challenges of the Aplastic Anemia Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Aplastic Anemia Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Aplastic Anemia Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Aplastic Anemia Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Aplastic Anemia Therapeutics market

## Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Aplastic Anemia Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Aplastic Anemia Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Aplastic Anemia Therapeutics market landscape? - Identify, understand and capitalize.

## Contents:

- 1
- 1
- 1.1 List of Tables
- 1.2 List of Figures
- 2 Aplastic Anemia Therapeutics - Introduction
- 2.1 Overview
- 2.2 Classification of Aplastic Anemia
- 2.2.1 Inherited Aplastic Anemia
- 2.2.2 Acquired Aplastic Anemia
- 2.3 Epidemiology
- 2.4 Etiology and Pathophysiology
- 2.4.1 Abnormalities of the Hematopoietic Stem Cells
- 2.4.2 Abnormal Hematopoietic Microenvironment
- 2.4.3 Immune Mediated Damage of the Hematopoietic Stem Cells
- 2.5 Risk Factors
- 2.6 Symptoms
- 2.7 Diagnosis of Aplastic Anemia
- 2.7.1 Physical Examination
- 2.7.2 Full Blood Count
- 2.7.3 Bone Marrow Examination
- 2.7.4 Liver Function Tests and Viral Studies
- 2.7.5 Vitamin B12 and Folate Levels
- 2.7.6 Autoantibody Screen

- 2.7.7 Tests to Detect a PNH Clone
- 2.7.8 Cytogenetic Investigations
- 2.7.9 Screening for Inherited Disorders
- 2.7.10 Radiological Investigations
- 2.8 Referral Pathway
- 2.9 Treatment
- 2.9.1 Primary Treatment
- 2.9.2 Supportive Treatment
- 2.10 GlobalData Pipeline Report Guidance
- 3 Aplastic Anemia Therapeutics - Market Characterization
- 3.1 Major Markets, Market Size (2006-2011)
- 3.2 Major Markets, Market Forecast (2011-2019)
- 3.3 Aplastic Anemia Market Size (2006-2011) - The US
- 3.4 Aplastic Anemia Market Forecast (2011-2019) - The US
- 3.5 Aplastic anemia Market Size (2006-2011) - The UK
- 3.6 Aplastic Anemia Market Forecast (2011-2019) - The UK
- 3.7 Aplastic Anemia Market Size (2006-2011) - France
- 3.8 Aplastic Anemia Market Forecast (2011-2019) - France
- 3.9 Aplastic Anemia Market Size (2006-2011) - Germany
- 3.10 Aplastic Anemia Market Forecast (2011-2019) - Germany
- 3.11 Aplastic Anemia Market Size (2006-2011) - Italy
- 3.12 Aplastic Anemia Market Forecast (2011-2019) - Italy
- 3.13 Aplastic Anemia Market Size (2006-2011) - Spain
- 3.14 Aplastic Anemia Market Forecast (2011-2019) - Spain
- 3.15 Aplastic Anemia Market Size (2006-2011) - Japan
- 3.16 Aplastic Anemia Market Forecast (2011-2019) - Japan
- 3.17 Drivers and Barriers for the Aplastic Anemia Market
- 3.17.1 Drivers for the Aplastic Anemia Market
- 3.18 Barriers for the Aplastic Anemia Market
- 3.18.1 Barriers for the Aplastic Anemia Market
- 3.19 Opportunity and Unmet Need
- 3.20 Key Takeaway
- 4 Aplastic Anemia Therapeutics - Competitive Assessment
- 4.1 Overview
- 4.1.1 Strategic Competitor Assessment
- 4.2 Profiles of Commonly Used Products in the Aplastic Anemia Market
- 4.2.1 ATGAM (lymphocyte immune globulin, anti-thymocyte globulin)
- 4.3 Key Takeaway
- 5 Aplastic Anemia Therapeutics - Pipeline Assessment
- 5.1 Overview
- 5.2 Strategic Pipeline Assessment
- 5.3 Aplastic Anemia Market - Pipeline by Phases of Development
- 5.3.1 Aplastic Anemia - Phase II/III Pipeline
- 5.3.2 Aplastic Anemia - Phase II Pipeline
- 5.3.3 Aplastic Anemia - Phase I Pipeline
- 5.4 Aplastic Anemia Pipeline by Mechanism of Action
- 5.5 Aplastic Anemia Technology Trends Analytical Framework
- 5.6 Molecule Profile for Drugs Under Clinical Development
- 5.6.1 Alemtuzumab
- 5.6.2 Eltrombopag
- 5.7 Key Takeaway
- 6 Aplastic Anemia - Clinical Trials Mapping
- 6.1 Clinical Trials by Country (The US, EU5 and Japan)
- 6.2 Clinical Trials by Phase
- 6.3 Clinical Trials by Trial Status
- 6.4 Overall Sponsors
- 6.5 Prominent Sponsors
- 7 Aplastic Anemia Therapeutics - Strategic Assessment
- 7.1 Aplastic Anemia Therapeutics - Implications for Future Market Competition
- 8 Aplastic Anemia Therapeutics - Future Players in the Market
- 8.1 Bellicum Pharmaceuticals, Inc.
- 8.1.1 Company Overview
- 8.1.2 Bellicum Pharmaceuticals, Inc. - Aplastic Anemia Pipeline
- 9 Aplastic Anemia Therapeutics - Expert Opinions
- 9.1 Important Data and Analysis from Key Opinion Leaders (KOLs)
- 9.1.1 Aplastic Anemia Overview (epidemiology, etiology, symptoms)
- 9.1.2 Diagnosis and Treatment
- 9.1.3 Market Characterization
- 10 Aplastic Anemia Therapeutics - Appendix
- 10.1 Definitions
- 10.2 Acronyms
- 10.3 Research Methodology
- 10.3.1 Coverage
- 10.3.2 Secondary Research
- 10.3.3 Forecasting
- 10.3.4 Primary Research
- 10.3.5 Expert Panel Validation
- 10.4 Contact Us
- 10.5 Disclaimer
- 10.6 Bibliography
- 1.1 List of Tables
- Table 1: Aplastic Anemia - Incidence, Major Markets, 2011
- Table 2: Causes of Aplastic Anemia
- Table 3: Aplastic Anemia Market, Seven Major Markets, Revenue (\$m), 2006 - 2011
- Table 4: Aplastic Anemia Market, Major Markets, Forecast (\$m), 2011 - 2019
- Table 5: Aplastic Anemia Market, The US, Revenue (\$m), 2006 - 2011
- Table 6: Aplastic Anemia Market, The US, Forecast (\$m), 2011 - 2019
- Table 7: Aplastic Anemia Market, The UK, Revenue (\$m), 2006 - 2011
- Table 8: Aplastic Anemia Market, The UK, Forecast (\$m), 2011 - 2019
- Table 9: Aplastic Anemia Market, France, Revenue (\$m), 2006 - 2011
- Table 10: Aplastic Anemia Market, France, Forecast (\$m), 2011 - 2019

Table 11: Aplastic Anemia Market, Germany, Revenue (\$m), 2006 - 2011
Table 12: Aplastic Anemia Market, Germany, Forecast (\$m), 2011 - 2019
Table 13: Aplastic Anemia Market, Italy, Revenue (\$m), 2006 - 2011
Table 14: Aplastic Anemia Market, Italy, Forecast (\$m), 2011 - 2019
Table 15: Aplastic Anemia Market, Spain, Revenue (\$m), 2006 - 2011
Table 16: Aplastic Anemia Market, Spain, Forecast (\$m), 2011 - 2019
Table 17: Aplastic Anemia Market, Japan, Revenue (\$m), 2006 - 2011
Table 18: Aplastic Anemia Market, Japan, Forecast (\$m), 2011 - 2019
Table 19: Competitive Analysis of Different Brands of ATG
Table 20: Aplastic Anemia - Phase II/III Pipeline
Table 21: Aplastic Anemia - Phase II Pipeline
Table 22: Aplastic Anemia - Phase I Pipeline
Table 23: Aplastic Anemia - Clinical Trials by Country, 2011
Table 24: Aplastic Anemia - Clinical Trials by Phase, 2011
Table 25: Aplastic Anemia - Clinical Trials by Status, 2011
Table 26: Aplastic Anemia, Overall Sponsors, 2011
Table 27: Aplastic Anemia - Prominent Sponsors, 2011
Table 28: Bellicum Pharmaceuticals, Inc. - Aplastic Anemia Pipeline

## 1.2 List of Figures

Figure 1: Development of Aplastic Anemia
Figure 2: Pathophysiology of Aplastic Anemia
Figure 3: Bone Marrow Biopsy in Aplastic Anemia
Figure 4: Referral Pathway
Figure 5: Treatment of Non-severe Acquired Aplastic Anemia in Adults
Figure 6: Treatment of Severe Acquired Aplastic Anemia in Adults
Figure 7: Aplastic Anemia Market, Seven Major Markets, Revenue (\$m), 2006 - 2011
Figure 8: Aplastic Anemia, Market Share (\$m), 2011
Figure 9: Aplastic Anemia Market, Major Markets, Forecast (\$m), 2011 - 2019
Figure 10: Aplastic Anemia, Seven Major Markets, Market Share (\$m), 2019
Figure 11: Aplastic Anemia Market, The US, Revenue (\$m), 2006 - 2011
Figure 12: Aplastic Anemia Market, The US, Forecast (\$m), 2011 - 2019
Figure 13: Aplastic Anemia Market, The UK, Revenue (\$m), 2006 - 2011
Figure 14: Aplastic Anemia Market, The UK, Forecast (\$m), 2011 - 2019
Figure 15: Aplastic Anemia Market, France, Revenue (\$m), 2006 - 2011
Figure 16: Aplastic Anemia Market, France, Forecast (\$m), 2011 - 2019
Figure 17: Aplastic Anemia Market, Germany, Revenue (\$m), 2006 - 2011
Figure 18: Aplastic Anemia Market, Germany, Forecast (\$m), 2011 - 2019
Figure 19: Aplastic Anemia Market, Italy, Revenue (\$m), 2006 - 2011
Figure 20: Aplastic Anemia Market, Italy, Forecast (\$m), 2011 - 2019
Figure 21: Aplastic Anemia Market, Spain, Revenue (\$m), 2006 - 2011
Figure 22: Aplastic Anemia Market, Spain, Forecast (\$m), 2011 - 2019
Figure 23: Aplastic Anemia Market, Japan, Revenue (\$m), 2006 - 2011
Figure 24: Aplastic Anemia Market, Japan, Forecast (\$m), 2011 - 2019
Figure 25: Opportunity and Unmet Need in the Aplastic Anemia Market, 2011
Figure 26: Strategic Competitor Assessment of the Major Marketed Products for Aplastic Anemia
Figure 27: Aplastic Anemia - Pipeline by Phase of Development, 2011
Figure 28: Aplastic Anemia Market - Clinical Pipeline by Mechanism of Action, 2011
Figure 29: Technology Trends Analytical Framework of the Aplastic Anemia Pipeline, 2011
Figure 30: Aplastic Anemia - Clinical Trials by Country, 2011
Figure 31: Aplastic Anemia - Clinical Trials by Phase, 2011
Figure 32: Aplastic Anemia - Clinical Trials by Status, 2011
Figure 33: Aplastic Anemia - Overall Sponsors, 2011
Figure 34: Aplastic Anemia - Prominent Sponsors, 2011
Figure 35: Implications for Future Market Competition in the Aplastic Anemia Therapeutics Market, 2011
Figure 36: Aplastic Anemia Therapeutics, Global, Key Data Inputs from KOL Interviews, November 2011
Figure 37: Aplastic Anemia, Global, Key Data Inputs from KOL Interviews, November 2011
Figure 38: Aplastic Anemia, Global, Key Data Inputs from KOL Interviews, November 2011
Figure 39: Aplastic Anemia, Global, Key Data Inputs from KOL Interviews, November 2011
Figure 40: GlobalData Market Forecasting Model

## Contents:

GlobalData, the industry analysis specialist, has released its new report, "Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global aplastic anemia therapeutics market. The report identifies the key trends shaping and driving the global aplastic anemia therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global aplastic anemia therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

## The Aplastic Anemia Market is Forecast to Show Slow Growth until 2019

GlobalData estimates that the global aplastic anemia therapeutics market was worth \$73.3m in 2011 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 1.1% to reach \$79.7m by 2019. **The current treatment options for aplastic anemia include allogeneic stem cell transplant and immunosuppressive therapy** which are primarily dominated by generics. There is no promising, industry-sponsored molecule in the late stage pipeline. Owing to these factors, the aplastic anemia market is expected to show slow growth until 2019.

## The Aplastic Anemia Market has Moderate Unmet Need

Current treatment options for aplastic anemia are allogeneic stem cell transplant or immunosuppressive therapy. Although these therapies are effective in approximately 70% of patients, stem cell transplant is associated with the risk of developing graft failure and graft-versus-host disease (GVHD). **Chances of relapse and further development to myelodysplastic syndrome (MDS) limit the use of immunosuppressive therapy.** Therefore, a moderate unmet need exists in the treatment of aplastic anemia.

## Scope for Entrants with Better Efficacy and Safety Profiles

The aplastic anemia market is moderately served by the currently marketed products as these are effective only in approximately 70% of patients, and are associated with serious complications and relapses. Therefore, the aplastic anemia market offers adequate opportunity for new entrants who can develop drugs that can reduce the chances of graft rejection, GVHD and relapses, together with better efficacy and safety profiles.

## Weak Pipeline Unlikely to Drive the Growth of Aplastic Anemia Market

GlobalData's analysis of the entire pipeline landscape shows that the late stage pipeline does not offer any immediate hope for aplastic anemia patients. There is no molecule in Phase III of development. The only molecule in Phase II/III is alemtuzumab. Alemtuzumab is under investigation as a conditioning regimen for patients with severe aplastic anemia who are undergoing allogeneic stem cell transplantation using matched unrelated donors and mismatched related donors, which is a very small set of patients. The trial is sponsored by the Mayo Clinic. Eltrombopag, which is currently under Phase II development, may give some hope for aplastic anemia patients and could be launched by 2018, driving the growth of the aplastic anemia market. This trial was initiated by the National Heart, Lung, and Blood Institute (NHLBI) in March 2011.

Companies Mentioned: Bellicum Pharmaceuticals, Inc

Ordering: Order Online - visit <http://www.researchandmarkets.com/reports/2114301>

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,  
Guinness Centre,  
Taylors Lane,  
Dublin 8,  
Ireland.

## RESEARCHANDMARKETS

Page 1 of 2

Printed Jun 20th 2014  
2:32:15 PM

## Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email [help@researchandmarkets.net](mailto:help@researchandmarkets.net)

## Order information

Please verify that the product information is correct and select the format you require.

## Product name

Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019

## Web Address

<http://www.researchandmarkets.com/reports/2114301>

## Office Code

OC8DIMRQSMWXTZ

## Report Formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Enterprisewide	<input type="text"/>	GBP 7,171
Electronic (PDF) - Site License	<input type="text"/>	GBP 4,781
Electronic (PDF) - Single User	<input type="text"/>	GBP 2,390

## Contact information

Please enter all the information below in **BLOCK CAPITALS**.

Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐

First Name: \_\_\_\_\_ Last Name: \_\_\_\_\_

Email Address: \_\_\_\_\_

Job Title: \_\_\_\_\_

Organisation: \_\_\_\_\_

Address: \_\_\_\_\_

City: \_\_\_\_\_

Postal / Zip Code: \_\_\_\_\_

Country: \_\_\_\_\_  
Phone Number: \_\_\_\_\_  
Fax Number: \_\_\_\_\_

**Please fax this form to:**  
**(646) 607-1907 or (646) 964-6609 (from USA)**  
**+353-1-481-1716 or +353-1-653-1571 (from Rest of World)**

### Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

<input type="checkbox"/> Pay by Credit Card:	<input type="checkbox"/> American Express <input type="checkbox"/> Diners Club <input type="checkbox"/> Master Card <input type="checkbox"/> Visa  Cardholder's Name: _____ Cardholder's Signature: _____ Expiry Date: _____ / _____ Card Number: _____ CVV Security Code: _____ Issue date: _____ / _____ (Diners Club only)
<input type="checkbox"/> Pay by Check:	Please post the check, accompanied by this form, to: <b>Research and Markets,</b> Guinness Centre, Taylors Lane, Dublin 8, Ireland.
<input type="checkbox"/> Pay by Wire Transfer:	Please transfer funds to:  Account Number: 83313083 Sort Code: 98-53-30 Swift Code: ULSBIE2D IBAN Number: IE78ULSB98533083313083 Bank Address: <b>Ulster Bank,</b> 27-35 Main Street Blackrock, Co. Dublin Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: \_\_\_\_\_

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at  
<http://www.researchandmarkets.com/info/terms.asp>

**Please fax this form to:**  
**(646) 607-1907 or (646) 964-6609 (from USA)**  
**+353-1-481-1716 or +353-1-653-1571 (from Rest of World)**